Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

J. A. Johnson; L. Gong; M. Whirl-Carrillo; B. F. Gage; S. A. Scott; C. M. Stein; J. L. Anderson; S. E. Kimmel; M. T.M. Lee; M. Pirmohamed; M. Wadelius; T. E. Klein; R. B. Altman

doi:10.1038/clpt.2011.185

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

J. A. Johnson, L. Gong, M. Whirl-Carrillo, B. F. Gage, S. A. Scott, C. M. Stein, J. L. Anderson, S. E. Kimmel, M. T.M. Lee, M. Pirmohamed, M. Wadelius, T. E. Klein, R. B. Altman

Research output: Contribution to journal › Review article › peer-review

553 Scopus citations

Abstract

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ∼50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb. org based on new developments in the field. 1.

Original language	English
Pages (from-to)	625-629
Number of pages	5
Journal	Clinical pharmacology and therapeutics
Volume	90
Issue number	4
DOIs	https://doi.org/10.1038/clpt.2011.185
State	Published - Oct 2011

Access to Document

10.1038/clpt.2011.185

Cite this

Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., Wadelius, M., Klein, T. E., & Altman, R. B. (2011). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clinical pharmacology and therapeutics, 90(4), 625-629. https://doi.org/10.1038/clpt.2011.185

@article{5eaeb7c6fd9e4208b0c0d496b63cbe33,

title = "Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing",

abstract = "Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ∼50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb. org based on new developments in the field. 1.",

author = "Johnson, {J. A.} and L. Gong and M. Whirl-Carrillo and Gage, {B. F.} and Scott, {S. A.} and Stein, {C. M.} and Anderson, {J. L.} and Kimmel, {S. E.} and Lee, {M. T.M.} and M. Pirmohamed and M. Wadelius and Klein, {T. E.} and Altman, {R. B.}",

year = "2011",

month = oct,

doi = "10.1038/clpt.2011.185",

language = "English",

volume = "90",

pages = "625--629",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

number = "4",

}

Johnson, JA, Gong, L, Whirl-Carrillo, M, Gage, BF, Scott, SA, Stein, CM, Anderson, JL, Kimmel, SE, Lee, MTM, Pirmohamed, M, Wadelius, M, Klein, TE & Altman, RB 2011, 'Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing', Clinical pharmacology and therapeutics, vol. 90, no. 4, pp. 625-629. https://doi.org/10.1038/clpt.2011.185

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

AU - Johnson, J. A.

AU - Gong, L.

AU - Whirl-Carrillo, M.

AU - Gage, B. F.

AU - Scott, S. A.

AU - Stein, C. M.

AU - Anderson, J. L.

AU - Kimmel, S. E.

AU - Lee, M. T.M.

AU - Pirmohamed, M.

AU - Wadelius, M.

AU - Klein, T. E.

AU - Altman, R. B.

PY - 2011/10

Y1 - 2011/10

N2 - Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ∼50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb. org based on new developments in the field. 1.

AB - Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ∼50% of warfarin dose variability. The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network develops peer-reviewed gene-drug guidelines that are published and updated periodically on http://www.pharmgkb. org based on new developments in the field. 1.

UR - http://www.scopus.com/inward/record.url?scp=80052962391&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.185

DO - 10.1038/clpt.2011.185

M3 - Review article

C2 - 21900891

AN - SCOPUS:80052962391

SN - 0009-9236

VL - 90

SP - 625

EP - 629

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 4

ER -

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

Abstract

Access to Document

Other files and links

Fingerprint

Cite this